Not the End of the Physician-Scientist

In 1984 Gordon N. Gill, professor of medicine at the University of California at San Diego, published an essay entitled “The End of the Physician Scientist?” He described how from the mid- 1960s to the early 1980s the biomedical research enterprise in the United States passed largely out of the realm of clinical investigators and into that of Ph.D. scientists working at the molecular leveL He also noted that in the United Kingdom and Europe the split between basic science and clini

Written byEugene Garfield
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

In 1984 Gordon N. Gill, professor of medicine at the University of California at San Diego, published an essay entitled “The End of the Physician Scientist?” He described how from the mid- 1960s to the early 1980s the biomedical research enterprise in the United States passed largely out of the realm of clinical investigators and into that of Ph.D. scientists working at the molecular leveL He also noted that in the United Kingdom and Europe the split between basic science and clinical medicine had been completed by the early 1970s. The clinician-scientist had become the “clinician-applier of basic science.” (American Scholar, vol. 53, 1984, p. 360.) “Like it or not,” Gill concluded, “the separation of physicians and scientists is well advanced.. . . Partial attention to either science or medicine is no longer enough” (p. 368).

Gill, while astutely describing a genuine and broad historic shift, I think too quickly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies